Trials / Unknown
UnknownNCT04573855
TREATMENT WITH ANTI-SARS-COV-2 IMMUNOGLOBULIN IN PATIENTS WITH COVID-19
TREATMENT WITH ANTI-SARS-COV-2 IMMUNOGLOBULIN IN PATIENTS WITH COVID-19: A PHASE I / II STUDY
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 41 (estimated)
- Sponsor
- D'Or Institute for Research and Education · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Phase I/II clinical trial for safety and efficacy evaluation of treatment with anti-SARS-CoV-2 equine immunoglobulin (F(ab')2) in hospitalized patients with COVID-19 not requiring of invasive ventilation support.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Anti-SARS-CoV-2 immunoglobulin | Treatment with Anti-SARS-CoV-2 immunoglobulin |
Timeline
- Start date
- 2020-12-01
- Primary completion
- 2021-02-28
- Completion
- 2021-03-31
- First posted
- 2020-10-05
- Last updated
- 2020-10-05
Source: ClinicalTrials.gov record NCT04573855. Inclusion in this directory is not an endorsement.